Literature DB >> 18518848

Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.

Lingling Chen1, Shengying Qin, Jing Xie, Jimin Tang, Lun Yang, Wen Shen, Xinzhi Zhao, Jing Du, Guang He, Guoyin Feng, Lin He, Qinghe Xing.   

Abstract

AIMS: Although many studies have been performed on CYP2C19, most of them have mainly examined the effects of the defective alleles CYP2C19(*)2 and CYP2C19(*)3. A comprehensive search for genetic polymorphisms of the CYP2C19 gene in the Chinese Han population has rarely been conducted. The present study was designed to determine the genetic basis of CYP2C19 polymorphisms. MATERIALS &
METHODS: We investigated the 5 -regulatory region, all the exons and their surrounding introns of the CYP2C19 gene in 400 unrelated healthy Chinese Han volunteers from four different geographical locations, namely Shanghai, Shantou, Shenyang and Xi'an, with a sample of 100 subjects in each population, using direct sequencing.
RESULTS: A total of 14 different CYP2C19 polymorphisms, including one novel variant (-2306G>A) in the enhancer region and a novel nonsynonymous one (905C>G, T302R) were identified. In addition, CYP2C19(*)1, (*)2, (*)3, (*)15 and (*)17 alleles showed frequencies of 69.7%, 24.7%, 3.3%, 1.2% and 1.2%, respectively, and CYP2C19(*)15 was the first detected in an Asian population. The frequencies of the prevalent defective alleles CYP2C19(*)2 and CYP2C19(*)3 in Chinese Han populations are similar to those in other Asians, and much higher than those reported in American European and other Caucasian populations. Haplotype analysis demonstrated CATCGG was the dominating haplotype with a frequency of 38.6% in the Chinese Han population. Furthermore, homology modeling analysis for CYP2C19 indicates that Thr302Arg could cause the displacement of heme.
CONCLUSION: This is the first study that systematically screened the polymorphisms of the whole CYP2C19 gene in a large Chinese Han population. The results suggest that a few low frequent variants show significant differences among the four populations, while the prevalent polymorphisms show no differences. Therefore, our database provides important information on CYP2C19 polymorphisms in the Chinese population, and could be helpful for future personalized medicine studies in Asian populations generally.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18518848     DOI: 10.2217/14622416.9.6.691

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  38 in total

1.  Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.

Authors:  Ersin Gumus; Ozgur Karaca; Melih O Babaoglu; Gökhan Baysoy; Necati Balamtekin; Hulya Demir; Nuray Uslu; Atilla Bozkurt; Aysel Yuce; Umit Yasar
Journal:  Eur J Clin Pharmacol       Date:  2011-11-11       Impact factor: 2.953

Review 2.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 3.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

4.  Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.

Authors:  Yipeng Ding; Dongchuan Xu; Xiyang Zhang; Hua Yang; Tingting Geng; Ping He; Jinjian Yao; Shengyang Yi; Heping Xu; Duoyi Wu; Xiang Wang; Tianbo Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Re-creation of the genetic composition of a founder population.

Authors:  William Klitz; Martin Maiers; Loren Gragert
Journal:  Hum Genet       Date:  2008-09-27       Impact factor: 4.132

6.  Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.

Authors:  Gregory L Kearns; J Steven Leeder; Andrea Gaedigk
Journal:  Drug Metab Dispos       Date:  2010-03-11       Impact factor: 3.922

7.  Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor.

Authors:  Yifan Zhang; Xiaoxue Zhu; Yan Zhan; Xiaojiao Li; Cai Liu; Yunting Zhu; Hong Zhang; Haijing Wei; Yu Xia; Hongbin Sun; Yongqiang Liu; Xiaojuan Lai; Yanchun Gong; Xuefang Liu; Yongguo Li; Yanhua Ding; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2020-06-17       Impact factor: 4.335

8.  Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

Authors:  Mirjana Novkovic; Dragan Matic; Jelena Kusic-Tisma; Nebojsa Antonijevic; Dragica Radojkovic; Ljiljana Rakicevic
Journal:  Eur J Clin Pharmacol       Date:  2017-12-19       Impact factor: 2.953

9.  Association study between FSHR Ala307Thr and Ser680Asn variants and polycystic ovary syndrome (PCOS) in Northern Chinese Han women.

Authors:  Lingyuan Fu; Zhaofeng Zhang; Aiping Zhang; Jianhua Xu; Xianliang Huang; Qiupeng Zheng; Yunlei Cao; Lei Wang; Jing Du
Journal:  J Assist Reprod Genet       Date:  2013-03-29       Impact factor: 3.412

10.  Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.

Authors:  Jen-Kuang Lee; Cho-Kai Wu; Jyh-Ming Juang; Chia-Ti Tsai; Juey-Jen Hwang; Jiuun-Lee Lin; Fu-Tien Chiang
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.